Vanguard Group
ACOR

Vanguard Group’s Acorda Therapeutics ACOR Stock Holding History

Vanguard Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,260
Closed -$254K – 4519
2024
Q1 		$254K Buy
19,260
+8,452
+78% +$123K ﹤0.01% 4140
2023
Q4 		$163K Buy
10,808
+74
+0.7% +$839 ﹤0.01% 4248
2023
Q3 		$161K Buy
+10,734
New +$162K ﹤0.01% 4288
2023
Q2 		– Sell
-7,989
Closed -$93.6K – 4598
2023
Q1 		$93.6K Buy
7,989
+73
+0.9% +$1.21K ﹤0.01% 4414
2022
Q4 		$121K Buy
7,916
+152
+2% +$1.77K ﹤0.01% 4372
2022
Q3 		$46K Sell
7,764
-139
-2% -$1.16K ﹤0.01% 4550
2022
Q2 		$73K Sell
7,903
-9,174
-54% -$163K ﹤0.01% 4566
2022
Q1 		$549K Hold
17,077
– – ﹤0.01% 4384
2021
Q4 		$817K Hold
17,077
– – ﹤0.01% 4316
2021
Q3 		$1.57M Buy
17,077
+53
+0.3% +$4.4K ﹤0.01% 4130
2021
Q2 		$1.62M Buy
17,024
+3,412
+25% +$298K ﹤0.01% 4031
2021
Q1 		$1.32M Sell
13,612
-1,556
-10% -$191K ﹤0.01% 3949
2020
Q4 		$1.26M Sell
15,168
-8,686
-36% -$799K ﹤0.01% 3773
2020
Q3 		$1.47M Sell
23,854
-9,544
-29% -$720K ﹤0.01% 3575
2020
Q2 		$2.94M Sell
33,398
-3,527
-10% -$373K ﹤0.01% 3318
2020
Q1 		$4.13M Sell
36,925
-5,105
-12% -$1M ﹤0.01% 3051
2019
Q4 		$10.3M Sell
42,030
-7,772
-16% -$1.96M ﹤0.01% 2845
2019
Q3 		$17.2M Sell
49,802
-1,800
-3% -$978K ﹤0.01% 2557
2019
Q2 		$47.5M Sell
51,602
-5,643
-10% -$6.93M ﹤0.01% 2127
2019
Q1 		$91.3M Buy
57,245
+6,384
+13% +$11.5M ﹤0.01% 1795
2018
Q4 		$95.1M Buy
50,861
+5,990
+13% +$13M ﹤0.01% 1706
2018
Q3 		$106M Buy
44,871
+4,547
+11% +$14.1M ﹤0.01% 1775
2018
Q2 		$139M Buy
40,324
+3,756
+10% +$11.5M 0.01% 1595
2018
Q1 		$104M Buy
36,568
+96
+0.3% +$287K ﹤0.01% 1695
2017
Q4 		$93.9M Buy
36,472
+972
+3% +$2.76M ﹤0.01% 1752
2017
Q3 		$101M Sell
35,500
-401
-1% -$1.06M ﹤0.01% 1712
2017
Q2 		$84.9M Buy
35,901
+1,404
+4% +$2.78M ﹤0.01% 1763
2017
Q1 		$86.9M Buy
34,497
+1,947
+6% +$5.6M ﹤0.01% 1739
2016
Q4 		$73.4M Sell
32,550
-973
-3% -$2.31M ﹤0.01% 1790
2016
Q3 		$84M Sell
33,523
-2,049
-6% -$6.11M ﹤0.01% 1676
2016
Q2 		$109M Buy
35,572
+6,327
+22% +$20.6M 0.01% 1462
2016
Q1 		$92.8M Buy
29,245
+1,880
+7% +$7.8M 0.01% 1535
2015
Q4 		$140M Buy
27,365
+750
+3% +$3.28M 0.01% 1228
2015
Q3 		$84.7M Buy
26,615
+653
+3% +$2.53M 0.01% 1555
2015
Q2 		$104M Buy
25,962
+1,081
+4% +$4.18M 0.01% 1496
2015
Q1 		$99.4M Buy
24,881
+1,188
+5% +$5.44M 0.01% 1499
2014
Q4 		$116M Buy
23,693
+129
+0.5% +$554K 0.01% 1309
2014
Q3 		$95.8M Buy
23,564
+381
+2% +$1.43M 0.01% 1386
2014
Q2 		$93.8M Buy
23,183
+73
+0.3% +$298K 0.01% 1438
2014
Q1 		$105M Buy
23,110
+980
+4% +$3.96M 0.01% 1319
2013
Q4 		$77.5M Buy
22,130
+1,060
+5% +$4.13M 0.01% 1487
2013
Q3 		$86.7M Buy
21,070
+627
+3% +$2.7M 0.01% 1337
2013
Q2 		$80.9M Buy
+20,443
New +$84.2M 0.01% 1309

Other funds holding ACOR

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group's ACOR Position: Q2 2024 in Review

Vanguard Group sold out of Acorda Therapeutics (ACOR) in Q2 2024, closing a stake of 19,260 shares — an estimated $254K sold.

Vanguard Group first reported a position in ACOR in Q2 2013 and held it in 43 quarters. The position peaked at $140M in Q4 2015. 2 funds tracked by Wall St. Rank hold ACOR as of Q2 2024.

  • Vanguard Group reported no remaining Acorda Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 19,260 Acorda Therapeutics shares in Q2 2024, an estimated $254K.
  • Vanguard Group first reported a position in Acorda Therapeutics in Q2 2013 and held it in 43 quarters.
  • Vanguard Group's Acorda Therapeutics position peaked at $140M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.